Q4 2022 EPS Estimates for Humana Inc. (NYSE:HUM) Reduced by Analyst

Humana Inc. (NYSE:HUMGet Rating) – Equities research analysts at Oppenheimer cut their Q4 2022 EPS estimates for shares of Humana in a report released on Thursday, January 19th. Oppenheimer analyst M. Wiederhorn now forecasts that the insurance provider will post earnings of $1.41 per share for the quarter, down from their previous estimate of $1.42. The consensus estimate for Humana’s current full-year earnings is $25.00 per share. Oppenheimer also issued estimates for Humana’s FY2023 earnings at $27.88 EPS, Q1 2024 earnings at $8.98 EPS, Q2 2024 earnings at $10.06 EPS, Q3 2024 earnings at $8.91 EPS, Q4 2024 earnings at $3.92 EPS, FY2024 earnings at $31.87 EPS and FY2025 earnings at $36.95 EPS.

Other analysts have also issued research reports about the company. Mizuho boosted their target price on Humana from $529.00 to $615.00 and gave the company a “buy” rating in a research report on Thursday, November 10th. SVB Leerink boosted their target price on Humana from $540.00 to $640.00 and gave the company an “outperform” rating in a research report on Thursday, November 3rd. The Goldman Sachs Group raised Humana from a “neutral” rating to a “buy” rating and boosted their target price for the company from $575.00 to $652.00 in a research report on Tuesday, December 13th. Wells Fargo & Company boosted their price target on shares of Humana from $558.00 to $610.00 in a research note on Tuesday, November 8th. Finally, Cowen boosted their price target on shares of Humana from $547.00 to $647.00 in a research note on Monday, November 7th. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $602.50.

Humana Stock Up 1.1 %

Shares of NYSE HUM opened at $497.30 on Friday. The firm has a market cap of $62.96 billion, a price-to-earnings ratio of 22.55, a PEG ratio of 1.25 and a beta of 0.76. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.48. Humana has a 52-week low of $363.73 and a 52-week high of $571.30. The business’s 50 day moving average is $516.00 and its two-hundred day moving average is $504.75.

Humana (NYSE:HUMGet Rating) last released its quarterly earnings results on Wednesday, November 2nd. The insurance provider reported $6.88 EPS for the quarter, beating the consensus estimate of $6.25 by $0.63. The firm had revenue of $22.80 billion for the quarter, compared to analyst estimates of $22.80 billion. Humana had a net margin of 3.07% and a return on equity of 19.99%.

Hedge Funds Weigh In On Humana

Several large investors have recently bought and sold shares of the stock. Dean Investment Associates LLC boosted its stake in Humana by 0.4% in the third quarter. Dean Investment Associates LLC now owns 4,338 shares of the insurance provider’s stock valued at $2,105,000 after acquiring an additional 19 shares in the last quarter. Private Trust Co. NA raised its holdings in shares of Humana by 10.6% in the third quarter. Private Trust Co. NA now owns 219 shares of the insurance provider’s stock valued at $106,000 after buying an additional 21 shares during the last quarter. Newbridge Financial Services Group Inc. raised its holdings in shares of Humana by 42.3% in the second quarter. Newbridge Financial Services Group Inc. now owns 74 shares of the insurance provider’s stock valued at $35,000 after buying an additional 22 shares during the last quarter. Clearstead Advisors LLC raised its holdings in shares of Humana by 12.9% in the second quarter. Clearstead Advisors LLC now owns 192 shares of the insurance provider’s stock valued at $90,000 after buying an additional 22 shares during the last quarter. Finally, Nicolet Advisory Services LLC raised its holdings in shares of Humana by 0.9% in the second quarter. Nicolet Advisory Services LLC now owns 2,522 shares of the insurance provider’s stock valued at $1,201,000 after buying an additional 23 shares during the last quarter. Institutional investors and hedge funds own 93.38% of the company’s stock.

Insider Buying and Selling

In related news, insider Timothy S. Huval sold 635 shares of the business’s stock in a transaction on Friday, December 16th. The shares were sold at an average price of $497.71, for a total transaction of $316,045.85. Following the completion of the transaction, the insider now owns 4,968 shares in the company, valued at $2,472,623.28. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Humana news, insider Timothy S. Huval sold 635 shares of the company’s stock in a transaction on Friday, December 16th. The shares were sold at an average price of $497.71, for a total value of $316,045.85. Following the completion of the transaction, the insider now owns 4,968 shares in the company, valued at $2,472,623.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David A. Jr/Ky Jones sold 15,000 shares of the company’s stock in a transaction on Wednesday, December 21st. The shares were sold at an average price of $501.72, for a total transaction of $7,525,800.00. Following the completion of the transaction, the director now owns 42,028 shares of the company’s stock, valued at approximately $21,086,288.16. The disclosure for this sale can be found here. Over the last quarter, insiders sold 51,570 shares of company stock worth $27,938,777. Corporate insiders own 0.39% of the company’s stock.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 27th. Investors of record on Friday, December 30th will be paid a dividend of $0.7875 per share. The ex-dividend date of this dividend is Thursday, December 29th. This represents a $3.15 dividend on an annualized basis and a dividend yield of 0.63%. Humana’s payout ratio is currently 14.29%.

Humana Company Profile

(Get Rating)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Stories

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.